The Experts below are selected from a list of 4686 Experts worldwide ranked by ideXlab platform
Cindy L Ehlers - One of the best experts on this subject based on the ideXlab platform.
-
effects of an orexin 2 receptor antagonist on Sleep and event related oscillations in female rats exposed to chronic intermittent ethanol during adolescence
Alcoholism: Clinical and Experimental Research, 2020Co-Authors: Leslie R Amodeo, Derek N Wills, Manuel Sanchezalavez, Cindy L EhlersAbstract:BACKGROUND Alcohol use is on the rise among women in the United States which is especially concerning since women who drink have a higher risk of alcohol-related problems. Orexin (hypocretin) receptor antagonists may have some therapeutic value for alcohol-induced insomnia; however, the use of this class of drugs following female adolescent binge drinking is limited. The current study will address whether adolescent intermittent ethanol (AIE) in female rats can result in lasting changes in Sleep Pathology and whether orexin-targeted treatment can alleviate these deficits. METHODS Following a 5-week AIE vapor model, young adult rats were evaluated on waking event-related oscillations (EROs) and EEG Sleep. Subsequently, AIE rats were treated with orexin receptor 2 (OX2 R) antagonist (MK-1064; 10, 20mg/kg) to test for modifications in Sleep Pathology and waking ERO. RESULTS Female AIE rats exhibited lasting changes in Sleep compared to controls. This was demonstrated by increased fragmentation of slow wave Sleep (SWS) and rapid eye movement Sleep, as well as reductions in delta and theta power during SWS. There was no impact of AIE on waking EROs. Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing Sleep fragmentation in AIE and controls. While treatment with MK-1064 did not impact Sleep EEG spectra, waking ERO energy was increased in delta, theta, and beta frequency bands. CONCLUSIONS These results demonstrate that AIE can produce lasting changes in Sleep in female rats, highly similar to what we previously found in males. Additionally, while the OX2 R antagonist promoted Sleep in both alcohol-exposed and unexposed rats, it did not reverse most of the alcohol-induced disruptions in Sleep. Thus, OX2 R antagonism may serve as a potential therapeutic strategy for the treatment of insomnia, but not the specific signs of alcohol-induced insomnia.
-
effect of suvorexant on event related oscillations and eeg Sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal
Sleep, 2019Co-Authors: Manuel Sanchezalavez, Derek N Wills, Jessica Benedict, Cindy L EhlersAbstract:Study objectives Insomnia is a prominent complaint in patients with alcohol use disorders (AUD). However, despite the importance of Sleep in the maintenance of sobriety, treatment options for Sleep disturbance associated with a history of AUD are currently limited. Recent clinical trials have demonstrated that suvorexant, a dual Hct/OX receptor antagonist, normalizes Sleep in patients with primary insomnia; yet, its potential for the treatment of Sleep Pathology associated with AUD has not been investigated in either preclinical or clinical studies. Methods This study employed a model whereby ethanol vapor exposure or control conditions were administered for 8 weeks to adult rats. Waking event-related oscillations (EROs) and EEG Sleep were evaluated at baseline before exposure and again following 24 hr of withdrawal from the exposure. Subsequently, the ability of vehicle (VEH) and two doses (10, 30 mg/kg IP) of suvorexant to modify EROs, Sleep, and the Sleep EEG was investigated. Results After 24 hr following EtOH withdrawal, the ethanol-treated group had increases in waking ERO θ and β activity, more fragmented Sleep (shorter duration and increased frequency of slow wave (SW) and rapid eye movement [REM] Sleep episodes), and increased θ and β power in REM and SW Sleep. Suvorexant induced a dose-dependent decrease in the latency to REM and SW Sleep onsets but also produced REM and SW Sleep fragmentation and increased β energy in waking EROs when compared with VEH. Conclusions Taken together, these studies suggest that suvorexant has overall Sleep-promoting effects, but it may exacerbate some aspects of Sleep and EEG Pathology.
Manuel Sanchezalavez - One of the best experts on this subject based on the ideXlab platform.
-
effects of an orexin 2 receptor antagonist on Sleep and event related oscillations in female rats exposed to chronic intermittent ethanol during adolescence
Alcoholism: Clinical and Experimental Research, 2020Co-Authors: Leslie R Amodeo, Derek N Wills, Manuel Sanchezalavez, Cindy L EhlersAbstract:BACKGROUND Alcohol use is on the rise among women in the United States which is especially concerning since women who drink have a higher risk of alcohol-related problems. Orexin (hypocretin) receptor antagonists may have some therapeutic value for alcohol-induced insomnia; however, the use of this class of drugs following female adolescent binge drinking is limited. The current study will address whether adolescent intermittent ethanol (AIE) in female rats can result in lasting changes in Sleep Pathology and whether orexin-targeted treatment can alleviate these deficits. METHODS Following a 5-week AIE vapor model, young adult rats were evaluated on waking event-related oscillations (EROs) and EEG Sleep. Subsequently, AIE rats were treated with orexin receptor 2 (OX2 R) antagonist (MK-1064; 10, 20mg/kg) to test for modifications in Sleep Pathology and waking ERO. RESULTS Female AIE rats exhibited lasting changes in Sleep compared to controls. This was demonstrated by increased fragmentation of slow wave Sleep (SWS) and rapid eye movement Sleep, as well as reductions in delta and theta power during SWS. There was no impact of AIE on waking EROs. Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing Sleep fragmentation in AIE and controls. While treatment with MK-1064 did not impact Sleep EEG spectra, waking ERO energy was increased in delta, theta, and beta frequency bands. CONCLUSIONS These results demonstrate that AIE can produce lasting changes in Sleep in female rats, highly similar to what we previously found in males. Additionally, while the OX2 R antagonist promoted Sleep in both alcohol-exposed and unexposed rats, it did not reverse most of the alcohol-induced disruptions in Sleep. Thus, OX2 R antagonism may serve as a potential therapeutic strategy for the treatment of insomnia, but not the specific signs of alcohol-induced insomnia.
-
effect of suvorexant on event related oscillations and eeg Sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal
Sleep, 2019Co-Authors: Manuel Sanchezalavez, Derek N Wills, Jessica Benedict, Cindy L EhlersAbstract:Study objectives Insomnia is a prominent complaint in patients with alcohol use disorders (AUD). However, despite the importance of Sleep in the maintenance of sobriety, treatment options for Sleep disturbance associated with a history of AUD are currently limited. Recent clinical trials have demonstrated that suvorexant, a dual Hct/OX receptor antagonist, normalizes Sleep in patients with primary insomnia; yet, its potential for the treatment of Sleep Pathology associated with AUD has not been investigated in either preclinical or clinical studies. Methods This study employed a model whereby ethanol vapor exposure or control conditions were administered for 8 weeks to adult rats. Waking event-related oscillations (EROs) and EEG Sleep were evaluated at baseline before exposure and again following 24 hr of withdrawal from the exposure. Subsequently, the ability of vehicle (VEH) and two doses (10, 30 mg/kg IP) of suvorexant to modify EROs, Sleep, and the Sleep EEG was investigated. Results After 24 hr following EtOH withdrawal, the ethanol-treated group had increases in waking ERO θ and β activity, more fragmented Sleep (shorter duration and increased frequency of slow wave (SW) and rapid eye movement [REM] Sleep episodes), and increased θ and β power in REM and SW Sleep. Suvorexant induced a dose-dependent decrease in the latency to REM and SW Sleep onsets but also produced REM and SW Sleep fragmentation and increased β energy in waking EROs when compared with VEH. Conclusions Taken together, these studies suggest that suvorexant has overall Sleep-promoting effects, but it may exacerbate some aspects of Sleep and EEG Pathology.
Derek N Wills - One of the best experts on this subject based on the ideXlab platform.
-
effects of an orexin 2 receptor antagonist on Sleep and event related oscillations in female rats exposed to chronic intermittent ethanol during adolescence
Alcoholism: Clinical and Experimental Research, 2020Co-Authors: Leslie R Amodeo, Derek N Wills, Manuel Sanchezalavez, Cindy L EhlersAbstract:BACKGROUND Alcohol use is on the rise among women in the United States which is especially concerning since women who drink have a higher risk of alcohol-related problems. Orexin (hypocretin) receptor antagonists may have some therapeutic value for alcohol-induced insomnia; however, the use of this class of drugs following female adolescent binge drinking is limited. The current study will address whether adolescent intermittent ethanol (AIE) in female rats can result in lasting changes in Sleep Pathology and whether orexin-targeted treatment can alleviate these deficits. METHODS Following a 5-week AIE vapor model, young adult rats were evaluated on waking event-related oscillations (EROs) and EEG Sleep. Subsequently, AIE rats were treated with orexin receptor 2 (OX2 R) antagonist (MK-1064; 10, 20mg/kg) to test for modifications in Sleep Pathology and waking ERO. RESULTS Female AIE rats exhibited lasting changes in Sleep compared to controls. This was demonstrated by increased fragmentation of slow wave Sleep (SWS) and rapid eye movement Sleep, as well as reductions in delta and theta power during SWS. There was no impact of AIE on waking EROs. Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing Sleep fragmentation in AIE and controls. While treatment with MK-1064 did not impact Sleep EEG spectra, waking ERO energy was increased in delta, theta, and beta frequency bands. CONCLUSIONS These results demonstrate that AIE can produce lasting changes in Sleep in female rats, highly similar to what we previously found in males. Additionally, while the OX2 R antagonist promoted Sleep in both alcohol-exposed and unexposed rats, it did not reverse most of the alcohol-induced disruptions in Sleep. Thus, OX2 R antagonism may serve as a potential therapeutic strategy for the treatment of insomnia, but not the specific signs of alcohol-induced insomnia.
-
effect of suvorexant on event related oscillations and eeg Sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal
Sleep, 2019Co-Authors: Manuel Sanchezalavez, Derek N Wills, Jessica Benedict, Cindy L EhlersAbstract:Study objectives Insomnia is a prominent complaint in patients with alcohol use disorders (AUD). However, despite the importance of Sleep in the maintenance of sobriety, treatment options for Sleep disturbance associated with a history of AUD are currently limited. Recent clinical trials have demonstrated that suvorexant, a dual Hct/OX receptor antagonist, normalizes Sleep in patients with primary insomnia; yet, its potential for the treatment of Sleep Pathology associated with AUD has not been investigated in either preclinical or clinical studies. Methods This study employed a model whereby ethanol vapor exposure or control conditions were administered for 8 weeks to adult rats. Waking event-related oscillations (EROs) and EEG Sleep were evaluated at baseline before exposure and again following 24 hr of withdrawal from the exposure. Subsequently, the ability of vehicle (VEH) and two doses (10, 30 mg/kg IP) of suvorexant to modify EROs, Sleep, and the Sleep EEG was investigated. Results After 24 hr following EtOH withdrawal, the ethanol-treated group had increases in waking ERO θ and β activity, more fragmented Sleep (shorter duration and increased frequency of slow wave (SW) and rapid eye movement [REM] Sleep episodes), and increased θ and β power in REM and SW Sleep. Suvorexant induced a dose-dependent decrease in the latency to REM and SW Sleep onsets but also produced REM and SW Sleep fragmentation and increased β energy in waking EROs when compared with VEH. Conclusions Taken together, these studies suggest that suvorexant has overall Sleep-promoting effects, but it may exacerbate some aspects of Sleep and EEG Pathology.
Gregory Tripsianis - One of the best experts on this subject based on the ideXlab platform.
-
the association between Sleep Pathology and depression a cross sectional study among adults in greece
Psychiatry Research-neuroimaging, 2020Co-Authors: Theofanis Vorvolakos, Eleni Leontidou, Dimitrios Tsiptsios, Christoph Mueller, Aspasia Serdari, Aikaterini Terzoudi, Evangelia Nena, Konstantinos Tsamakis, Theodoros C Constantinidis, Gregory TripsianisAbstract:Abstract A cross-sectional population based study was conducted in order to evaluate the potential association of Sleep characteristics with depression using self-reported questionnaires and taking into account several socio-demographic, lifestyle and health related characteristics. 957 participants aged between 19 and 86 years old were enrolled in our study. Depression symptoms were assessed using the Beck Depression Inventory. Participants self-reported their daily Sleep habits and filled in the Epworth Sleepiness Scale, Athens Insomnia Scale, Pittsburgh Sleep Quality Index and Berlin Questionnaire. Overall prevalence of depression was 28.4%. Depression symptoms were more prominent among minority groups. Subjects with depression reported shorter Sleep duration and had reduced Sleep efficiency. In patients with depression mean Sleep duration was reduced by 23 min and mean Sleep efficiency by 4%. Patients with depression were at higher risk of insomnia, poor Sleep quality and obstructive Sleep apnea, but not of excessive daytime Sleepiness. Concerning insomnia subtypes, depression was associated with difficulties maintaining Sleep and early morning awakening, but not problems initiating Sleep. Sleep disturbances are highly prevalent in depression and our findings support early pharmacological or cognitive behavioral interventions in order to address this key depression-associated symptom. Only addressing problems initiating Sleep might not be sufficient in depression.
Peter B Kang - One of the best experts on this subject based on the ideXlab platform.
-
Sleep Pathology in creutzfeldt jakob disease
Journal of Clinical Sleep Medicine, 2016Co-Authors: Peter B Kang, Gabriela De Bruin, Leo H Wang, Beth Ann Ward, Beau M Ances, Miranda M Lim, Robert C BucelliAbstract:Study Objectives:Associations between Sleep and neurodegenerative diseases have become increasingly evident. This study aims to characterize the prevalence and type of Sleep Pathology in Creutzfeld...
-
the spectrum of Sleep Pathology in definite creutzfeldt jakob disease p4 282
Neurology, 2016Co-Authors: Peter B Kang, Gabriela De Bruin, Leo H Wang, Beau M Ances, Miranda Lim, Bob BucelliAbstract:Objective: To identify the prevalence and type(s) of Sleep Pathology in Creutzfeldt-Jakob disease (CJD). Background: Sleep disorders are strongly associated with multiple neurodegenerative diseases and impact quality of life. The relationship between Sleep and CJD, a rapidly progressive, fatal neurodegenerative dementia, has not been well characterized. Design/Methods: We performed a retrospective analysis of Sleep signs and symptoms in a cohort of patients with definite CJD (n = 28; 26 sporadic, 2 familial; age range 42-76). Polysomnography (PSG) was performed on 14 patients. Results: While only 5 of 28 patients carried a premorbid Sleep diagnosis, signs/symptoms of Sleep dysfunction were present in 25. Eleven reported symptoms of hypersomnia, and 13 of insomnia. Seven met criteria for restless legs symptoms and/or periodic limb movements in Sleep, and nine reported parasomnias. Of the 14 patients with PSG: One did not show Sleep, seven (54[percnt]) had poorly formed Sleep spindles and/or K-complexes, and ten (77[percnt]) met clinical criteria for Sleep-disordered breathing; three of 8 (38[percnt]) had Rapid Eye Movement (REM) Sleep without atonia, two of which met clinical criteria for a diagnosis of REM behavior disorder. Median total Sleep time was 226 (IQR = 195-282) minutes. Median Sleep efficiency was 58.5 [percnt] (IQR = 41 - 65.5 [percnt]). Median time in REM Sleep was 0.35[percnt] (IQR = 0 - 7.125 [percnt]). Median periodic limb movement index was 0 per hour (IQR = 0 - 19.825) with 5 patients (42[percnt]) demonstrating periodic limb movements on PSG. Conclusions: Sleep abnormalities are common in CJD and represent a potentially treatable comorbidity associated with this devastating disease. Screening for Sleep Pathology may be indicated in the evaluation of patients with suspected CJD. Longitudinal studies are warranted to determine the significance of Sleep abnormalities in CJD diagnosis and whether Sleep measures can serve as biomarkers of disease progression. Disclosure: Dr. Kang has nothing to disclose. Dr. De Bruin has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Lim has nothing to disclose. Dr. Ances has nothing to disclose. Dr. Bucelli has nothing to disclose.